Haleon plc (HLN)
The company now
Haleon, the consumer health company behind Sensodyne, Panadol, Advil and Centrum, reported first-half 2026 revenue of £5,602m on 30 July 2026, up 2.2% 2.
Organic revenue growth, which leaves out currency swings and business disposals, was 2.6%, made of 2.1% from price and 0.5% from volume and mix 2.
Adjusted operating profit rose 8.2% at constant currency to £1,364m, while reported operating profit fell 2.6% to £1,172m because of restructuring costs 2.
The weakest area was respiratory health, where organic revenue fell 4.7% after a weak cold and flu season, particularly in North America, Central and Eastern Europe and China 2.
Haleon says its full-year 2026 outlook is unchanged, and its financial timetable lists a third-quarter 2026 trading statement for 29 October 2026 2.
As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.
Newer filings are on file since this was written; an update is queued.